Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE). (2021). SKIN The Journal of Cutaneous Medicine, 5(1), s15. https://doi.org/10.25251/skin.5.supp.15